Holen Sie sich die Stockscreener-App
3.60
6.51%
0.22
Handel nachbörslich:
3.76
0.16
+4.44%
Schlusskurs vom Vortag:
$3.38
Offen:
$3.4
24-Stunden-Volumen:
1.77M
Relative Volume:
0.97
Marktkapitalisierung:
$1.02B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.04M
KGV:
-4.3902
EPS:
-0.82
Netto-Cashflow:
$-122.99M
1W Leistung:
+10.09%
1M Leistung:
+35.85%
6M Leistung:
+135.29%
1J Leistung:
+36.88%
1-Tages-Spanne:
$3.37
$3.62
1-Wochen-Bereich:
$3.15
$3.62
52-Wochen-Spanne:
$1.01
$3.62
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Vergleichen Sie ERAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
3.60 | 958.95M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks - simplywall.st
Aug Breakouts: Is Erasca Inc stock a buy for dividend growthEarnings Growth Report & AI Optimized Trading Strategy Guides - moha.gov.vn
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Mizuho Maintains Erasca (ERAS) Outperform Recommendation - Nasdaq
Check Out Erasca Inc (ERAS)’s Trade Data Rather Than the Analysts’ Views - Setenews
Mizuho raises Erasca stock price target to $5 on RAS space optimism - Investing.com Canada
Erasca price target raised to $5 from $4 at Mizuho - TipRanks
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Hold" by Analysts - MarketBeat
Affinity Asset Advisors LLC Grows Stock Holdings in Erasca, Inc. $ERAS - Defense World
Will Erasca Inc. stock outperform international peers2025 Top Gainers & Fast Gaining Stock Reports - Newser
Gitlab, Acadia Healthcare, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results - Insider Monkey
Moving Averages: Why Erasca Inc. stock could be next big winnerInsider Buying & Momentum Based Trading Signals - moha.gov.vn
Unusually active option classes on open October 8th - MSN
Erasca to Present at the 8th Annual Evercore Healthcare Conference - The Manila Times
Adversity is less terrifying than hope: Erasca Inc (ERAS) - Setenews
Understanding Erasca Inc.’s price movementPortfolio Risk Summary & High Yield Equity Trading Tips - newser.com
Will Erasca Inc. stock benefit from automation2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
Erasca Inc. stock chart pattern explainedJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Why Erasca Inc. stock remains on watchlistsWeekly Stock Analysis & Free Weekly Watchlist of Top Performers - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire
ErascaTargeting Cancer's Most Commonly Mutated Pathway - RTTNews
Analyzing Precision BioSciences (NASDAQ:DTIL) and Erasca (NASDAQ:ERAS) - Defense World
HC Wainwright Issues Optimistic Estimate for Erasca Earnings - Defense World
Heatmap analysis for Erasca Inc. and competitorsEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
Analyzing net buyer seller activity in Erasca Inc.July 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Using fundamentals and technicals on Erasca Inc.IPO Watch & Risk Managed Investment Signals - newser.com
HC Wainwright Comments on Erasca’s Q1 Earnings (NASDAQ:ERAS) - Defense World
Why Erasca Inc. stock could see breakout soonTrade Performance Summary & AI Optimized Trade Strategies - newser.com
Is Erasca Inc. stock poised for growthQuarterly Growth Report & Weekly Top Performers Watchlists - newser.com
Erasca, Inc. Reports Q3 2025 Financial Results - MSN
Guggenheim raises Erasca stock price target to $5 on pipeline progress By Investing.com - Investing.com South Africa
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):